beta-carotene (generic name)
- Auto Immune Conditions
- Bladder & Kidney Health
- Brain & Nervous System
- Care Transitions
- Dental Health
- Emotional Health
- Eye Health
- Falls Prevention
- Financial Planning
- General Safety
- Health Care Basics
- Healthy Living
- Hearing Loss
- Heart Health
- High Blood Pressure
- Life Transitions
- Lung Health
- Men's Health
- Nutrition & Weight Management
- Pain Management
- Preventive Health
- Sexual Health
- Stomach & Digestive Health
- Stress & Anxiety
- Women's Health
Interactions with Drugs
Preliminary studies in animals indicate that beta-carotene supplementation, when combined with heavy alcohol consumption, may increase liver toxicity and promote cancer.
Cigarette smoking decreases serum concentrations of beta-carotene and other carotenoids and depletes body stores of beta-carotene. However, oral beta-carotene supplementation should not be recommended in smokers because supplemental beta-carotene in certain doses is associated with a significantly higher risk of lung and prostate cancer in smokers. Smokers and people with a history of asbestos exposure should avoid taking beta-carotene supplements.
Cholestyramine (Questran®) and colestipol (Colestid®) can reduce the absorption of fat-soluble vitamins, including beta-carotene. Serum levels of beta-carotene can be reduced, but this is probably only in proportion to the lowering of cholesterol (on which beta-carotene is transported). Supplements are not usually necessary.
Colchicine can cause disruption of intestinal mucosal function, resulting in malabsorption of beta-carotene.
Taking beta-carotene in combination with selenium, vitamin C, and vitamin E appears to decrease the effectiveness of the combination of simvastatin (Zocor®) and niacin. Theoretically, beta-carotene could reduce the effectiveness of other HMG-CoA reductase inhibitors ("statins") such as atorvastatin (Lipitor®), fluvastatin (Lescol®), lovastatin (Mevacor®), and pravastatin (Pravachol®).
Mineral oil reduces absorption of fat-soluble vitamins, including beta-carotene.
Oral neomycin sulfate can reduce beta-carotene absorption, but short-term use is unlikely to have a significant effect.
Orlistat (Xenical®) can decrease the absorption of beta-carotene and other fat-soluble vitamins. It is recommended that patients take a multivitamin supplement, and separate the dosing time by at least two hours from orlistat.
Loss of stomach acid can reduce the absorption of a single dose of beta-carotene. Examples of proton pump inhibitors (PPIs) include esomeprazole (Nexium®), lansoprazole (Prevacid®), omeprazole (Prilosec®, Losec®), rabeprazole (Aciphex®), and pantoprazole (Protonix®, Pantoloc®).
Interactions with Herbs and Dietary Supplements
Consumption of a natural carotenoid mixture has been shown to lower the increase in oxidative stress induced by the fish oil. This carotenoid mixture may also enhance the plasma triglyceride-lowering effect of the fish oil.
Iron supplementation in infants with marginal vitamin A status has led to lower plasma vitamin A concentrations and greater vitamin A liver stores. Some researchers recommend that iron supplementation in infants should be accompanied by measures to improve vitamin A status.
Beta-carotene supplementation has been shown to lower serum lutein concentrations. Lutein from food sources does not seem to result in the decrease in beta-carotene concentrations that accompanies administration of lutein supplements.
Plant sterols have been shown to reduce beta-carotene bioavailability in some studies and not to have a significant effect in others. The effects on cholesterol levels are also unproven.
Supplementation of beta-carotene may decrease the vitamin E concentration in tissues.
This information is based on a systematic review of scientific literature and consensus statements, peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Ethan Basch, MD, MSc, MPhil (Memorial Sloan-Kettering Cancer Center); Dawn Costa, BA, BS (Natural Standard Research Collaboration); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Natasha Tiffany, MD (Massachusetts General Hospital); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Christine Ulbricht, BS (University of Massachusetts); Wendy Weissner, BA (Natural Standard Research Collaboration).